Difference between revisions of "Profiles"
Jump to navigation
Jump to search
(48 intermediate revisions by 3 users not shown) | |||
Line 6: | Line 6: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ||
− | *[[Media: | + | *<td nowrap>[[Media:Atherosclerosis_Biomarkers_Profile_Jun2024.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile: ''Maintenance draft''. June, 2024 <b>DOI:10.1148/QIBA/202406</b>]]</td nowrap> |
− | *[[Media: | + | **[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile. March 28, 2023 <b>DOI:10.1148/QIBA/20230328</b>]] |
− | *[[Media: | + | *<td nowrap>[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023Dec19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023 <b>DOI:10.1148/QIBA/20231219</b> ]] |
− | *[[Media: | + | *<td nowrap>[[Media:QIBACTVol TumorVolumeChange 2022Jul21.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022 <b>DOI:10.1148/QIBA/20220721</b>]] |
− | *[[Media: | + | *<td nowrap>[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022 <b>DOI:10.1148/QIBA/20221215</b>]]</td nowrap> |
− | *[[Media: | + | *<td nowrap>[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|MR Elastography of the Liver, Clinically Feasible Profile: ''Maintenance draft''. November 7, 2023 <b>DOI:10.1148/QIBA/20231107</b>]]</td nowrap> |
+ | **[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver, Clinically Feasible Profile. February 2, 2022.]] | ||
− | *[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, | + | *[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid, Clinically Feasible Profile. June 3, 2022.]] |
− | *[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016 | + | |
− | ::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | + | *<td nowrap>[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023 <b>DOI:10.1148/QIBA/20230615</b>]]</td nowrap> |
+ | *[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.]] | ||
+ | ::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0. December, 2014.]] | ||
+ | |||
+ | *<td nowrap>[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf| US Shear Wave Speed for Liver Fibrosis, Clinically Feasible Profile. January 15, 2024 <b>DOI:10.1148/QIBA/20240115</b>]]</td nowrap> | ||
+ | ::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E. December 28, 2023]] | ||
+ | ::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible Site Assessment. January 26, 2023]] | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
Line 26: | Line 33: | ||
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]] | ::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]] | ||
− | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]] | + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]] |
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] | ||
Line 39: | Line 46: | ||
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
− | *[[Media:QIBA US | + | *[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf| US Volume Blood Flow Profile, Consensus version 2024-01-05]] |
− | |||
− | |||
− | |||
− | |||
− | ''' | + | *[[Media:MRI-Based_PDFF_of_the_Liver_QIBA_Profile_2024_06-19_CONSENSUS-maintenance.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver, Consensus Profile: ''Maintenance draft.'' June 19, 2024]] |
+ | **[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver, Consensus Profile. December 4, 2023]] | ||
− | + | *[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]] | |
− | |||
− | *[[Media:QIBA DCE- | ||
+ | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | ||
Line 62: | Line 65: | ||
− | '''[[Media:QIBA Profiles and Clinical Applications- | + | '''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]''' |
Latest revision as of 18:16, 11 July 2024
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023 DOI:10.1148/QIBA/20230615
- PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)